Search PubMed⌕ Search

Biomedical subjects

T Nishimura

Publications and source records attributed to T Nishimura.

At least 1,225 records · Page 68Linked to original sources
PubMed1986

Partial purification and characterization of epidermal growth factor in human breast milk.

Human epidermal growth factor (hEGF), a potent growth stimulator of many tissues in culture, has been isolated from human urine and subsequently identified in many human biological fluids including breast milk. In this study, partial purification and characterization of hEGF-like substance(s) in human milk were performed using homologous hEGF radioimmunoassay (RIA) and radioreceptor assay (RRA). hEGF-like material(s) was extracted from pooled human milk by ethanol precipitation, followed by adsorption to cation- and anion-exchange resin. DEAE-Sephadex G-25 ion-exchange chromatography of human milk extracts revealed three major components with hEGF activity (peak I, II, III) eluted with a linear gradient by ammonium acetate. The competitive binding curves for these components were parallel to those for standard hEGF in both RIA and RRA. The apparent molecular weight of peak I was approximately 6,500 and that of peak II and III was approximately 7,000 by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The pI value for peak I was approximately 4.5 and that for peaks II and III was approximately 5.0 by isoelectric focusing. These data are comparable to the size and charge heterogeneity of hEGF in human urine extracts. In conclusion, the major components of hEGF in human milk appear to be physicochemically, immunologically and biologically (receptor binding activity) indistinguishable from hEGF of urinary origin.

Epidermal Growth Factor↗
PubMed1986

New bioptic method for submucosal tumor of the gastrointestinal tract.

Biopsy for the submucosal tumor has not been established and it is extremely rare that tumor tissues are obtained by usual biopsy forceps except in cases showing ulceration. Moreover, tumor tissues from the ulcerated site often showed degeneration or necrosis, and are difficult for pathohistological diagnosis. In addition, the biopsies are often associated with bleeding. We have developed a new biopsy method. Briefly, a small amount of pure ethanol is injected topically into the surface of submucosal tumor to produce a small ulcer for biopsy, and several days later a biopsy specimen is obtained from the exposed tumor at the ulcer bottom. We performed this method for 12 lesions in 12 cases. In 64 of 100 bioptic specimens, tumor tissue was obtained and in all cases pathohistological diagnosis could be established. We believe this method will be important to determine the indication of endoscopic treatment or surgical operation, and for follow up observation.

Adult↗
PubMed1986

[Percutaneous transluminal angioplasty in subclavian artery stenosis].

The technique of percutaneous transluminal angioplasty (PTA) that was introduced initially by Dotter and Judkins in 1964 has been applied to various arterial stenoses and some occlusive lesions and has advanced dramatically with the development of the Grüntzig catheter in the treatment of peripheral vascular disease. However, the application to occlusive disease in brachiocephalic arteries is still considered to be disputable and has been made only in selective cases, especially in Japan. We report here a case with stenosis of the left subclavian artery successfully treated with PTA. The patient was 66 year-old man, who had been suffering from transient attacks of vertigo, ataxia, visual disturbance and the left arm claudication. Blood pressure was 150/92 mmHg in the right arm and 110 mmHg in systole in the left arm. Diagnostic arteriography identified the right carotid artery occlusion at its origin and significant stenosis in the proximal left subclavian artery. PTA under fluoroscopic control was performed by passing dilating catheter in antegrade fashion by Seldinger method through the left femoral artery. Anatomic correction was achieved without hemorrhagic or embolic complications. Systolic blood pressure gradient measured at the brachial artery level disappeared immediately after PTA and symptomatic relief was obtained completely. One month later, wide patency of the left subclavian artery and sufficient antegrade flow in the vertebral artery were confirmed angiographically. During follow-up period of 4 months, the patient was asymptomatic. We reviewed the literature reporting PTA for occlusive disease in brachiocephalic arteries and discussed its problems and possibilities, especially for the treatment of subclavian artery stenosis.

Aged↗
PubMed1986

[Non-invasive evaluation of right ventricular pressure in children with heart diseases: quantitative assessment by thallium myocardial imaging].

201-thallium myocardial imaging studies were performed to evaluate systolic pressures in the right ventricle of 194 patients. These patients were classified to four groups. Group A (95 cases) consists of 77 patients with congenital cardiac disease, five patients with primary pulmonary hypertension, and 13 patients with history of MCLS. Congenital cardiac diseases included 30 patients with tetralogy of Fallot, 20 with ventricular septal defect, nine with atrial septal defect, and eight with pulmonary stenosis. Group B (35 cases); preoperative state of transposition of the great arteries. Group C (43 cases); post-operative state of congenital cardiac disease whose pre-operative right ventricular systolic pressures represented more than 70% of the left ventricular systolic pressures. This group included 31 patients with tetralogy of Fallot, seven with ventricular septal defect, four with atrial septal defect and one with patent ductus arteriosus. Group D (21 cases); post-operative state of transposition of the great arteries. Fifteen min after intravenous infusion of 30-50 microCi/kg 201-TlCl, myocardial images were obtained in five projections (anterior, LAO 30 degrees, 45 degrees, 60 degrees, and lateral). The angles were determined to demonstrate clearly the interventricular septum and the ventricular free wall. The images of end-diastolic phase were obtained using the ECG-synchronized gated method in each projection. The region of interest (ROI) was defined as a section or slice by drawing two lines perpendicular to the septum, and the counts of the systemic and pulmonic ventricular free wall (Cs and Cp) were analyzed to evaluate the pressure of the pulmonic ventricle. The pressures of the ventricles were obtained by cardiac catheterization performed concomitantly with the cardiac imaging.(ABSTRACT TRUNCATED AT 250 WORDS)

Age Factors↗
PubMed1986

Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells.

The pharmacokinetics of aclarubicin, a new anthracycline antibiotic, was studied in five patients with acute leukemia or in L1210 cell suspension. Aclarubicin disappeared very rapidly from plasma and whole blood after administration at a dose of 20 mg per patient by iv bolus injection. The concentration of active metabolite M1, on the other hand, increased for up to 2 or 4 hrs after administration and exceeded that of aclarubicin, and then remained at much higher concentrations than aclarubicin for up to 24 hrs after administration. In addition, the levels of aclarubicin and its metabolites in whole blood were much higher than the corresponding plasma levels in four of the patients. The drug concentrations in blood cells of 11 patients determined 4 hrs after administration showed a significant positive correlation with leukocyte counts. Moreover, the concentration of aclarubicin and its metabolites was found to be much higher in the leukocyte fraction than in the erythrocyte fraction in vivo and in vitro. These findings indicate that aclarubicin and its metabolites in blood cells were mainly accumulated in leukocytes. In the study of intracellular drug distribution in L1210 cells, the largest amount of aclarubicin was incorporated into the nuclear fraction. This suggests a close relationship between the pronounced drug accumulation in leukocytes and the high affinity of aclarubicin for DNA.

Aclarubicin↗
PubMed1986

Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.

DBA/2 mice implanted i.p. with an aclarubicin (ACR)-resistant subline of L5178Y cells survived 4- to 5-fold longer than those with the parental cells; and animals with the Adriamycin- or bleomycin-resistant subline displayed an intermediate survival period. The i.p. treatment of mice with cyclophosphamide markedly enhanced i.p. growth of the ACR-resistant cells, suggesting that a certain host defense mechanism participates in the lower transplantability. In vitro, the ACR-resistant subline showed much higher sensitivity to natural killer cells. The i.p. pretreatment with anti-asialo-GM1 antibody markedly reduced the mean survival period of mice implanted i.p. with the ACR-resistant cells, suggesting that natural killer cells play an important role in the defense against transplantation of the ACR-resistant cells.

Aclarubicin↗
PubMed1986

[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field].

Laboratory and clinical studies on imipenem/cilastatin sodium were carried out and the obtained results were summarized below. The antibacterial activity of imipenem against clinical isolates of S. aureus, E. coli, K. pneumoniae, Salmonella sp., S. marcescens and P. aeruginosa was measured by the plate dilution method with an inoculum size of 10(6) cells/ml. The growth of S. aureus was inhibited at an imipenem concentration of 0.025 microgram/ml or lower. The susceptibility distribution of E. coli to imipenem ranged from 0.1 to 1.56 micrograms/ml, and the peak of the distribution was at 0.1 microgram/ml. The peak of the susceptibility distribution of K. pneumoniae was 0.2 microgram/ml, and those of S. marcescens and Salmonella ranged from 0.2 to 1.56 micrograms/ml and from 0.1 to 0.39 microgram/ml, respectively. The growth of P. aeruginosa was inhibited at a concentration of imipenem at 6.25 micrograms/ml. For a pharmacokinetic study, imipenem/cilastatin sodium was given to 1 patient in a single dose of 10 mg/kg or 20 mg/kg by drip infusion over 1 hour. With drip infusion of imipenem/cilastatin sodium, the peak plasma levels obtained with the two doses (10 and 20 mg/kg) were 20.6/26.4 micrograms/ml and 19.4/36.5 micrograms/ml, respectively on completion of the infusion. Clinical responses to imipenem/cilastatin sodium were excellent in 6 patients and fairly good in 1 patient, and the clinical effectiveness ratio was 85.7%. No side effect was observed except for elevations of GOT and GPT in 1 patient.

Bacteria↗
PubMed1986

[Pharmacokinetic and clinical studies of cefotiam in mature neonates].

Pharmacokinetic and clinical studies on cefotiam (CTM) in mature neonates were carried out. The results were summarized as follows: The serum peak level of CTM after intravenous bolus injection at a single dose of 10 mg/kg was found at 15 minutes after the injection. The serum peak level was 32.9 micrograms/ml in a 1 day-old neonate and it was 17.7 micrograms/ml in a 4 day-old neonate. Serum levels at 6 hours after injection were 4.5 micrograms/ml and 0.7 microgram/ml for the 1 day-old and the 4 day-old, respectively. Half-lives were 2.1 and 1.2 hours in the 1 and 4 day-old neonates, respectively. Serum peak levels of CTM at 15 minutes after intravenous bolus injection at a single dose of 20 mg/kg were 40.9 micrograms/ml in a 1 day-old neonate and 36.5 micrograms/ml in a 5 day-old neonate. Serum levels of CTM at 6 hours were 8.0 micrograms/ml in the 1 day-old neonate and 2.3 micrograms/ml in the 5 day-old neonate. Half-lives were 2.5 and 1.5 hours in the 1 and 5 day-old neonates, respectively. With each dosage, the younger showed extended half-lives. A dose-response relationship was observed. In 2 cases of 2 day-old neonates given CTM 20 mg/kg by 30-minute intravenous drip infusion, the mean peak concentration at the termination of the infusion was 25.1 micrograms/ml. Even after 6 hours the concentration was found at 8.7 micrograms/ml. Half-lives were 2.9 and 3.7 hours. Urinary excretion rates of CTM in 1 to 5 day-old neonates were as low as about 20% in any of cases subjected to a 10 mg/kg intravenous bolus injection, a 20 mg/kg intravenous bolus injection a 20 mg/kg 30-minute intravenous drip infusion. It was possible to evaluate the efficacy of CTM in only 1 case of pneumonia. CTM was clinically and bacteriologically effective in this case. No abnormal clinical symptoms and findings were observed in all of the 5 cases.

Cefotaxime↗